442 related articles for article (PubMed ID: 22623155)
1. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1.
Li L; Yuan L; Luo J; Gao J; Guo J; Xie X
Clin Exp Med; 2013 May; 13(2):109-17. PubMed ID: 22623155
[TBL] [Abstract][Full Text] [Related]
2. [Growth inhibition of human hepatocellular carcinoma by miRNA-204 via down-regulation of Bcl-2 and Sirt1 expression].
Li K; Xyu Q; Liu X; Liu Q; Wang M
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Feb; 31(2):168-72. PubMed ID: 25652855
[TBL] [Abstract][Full Text] [Related]
3. MiR-34a inhibits migration and invasion by regulating the SIRT1/p53 pathway in human SW480 cells.
Lai M; Du G; Shi R; Yao J; Yang G; Wei Y; Zhang D; Xu Z; Zhang R; Li Y; Li Z; Wang L
Mol Med Rep; 2015 May; 11(5):3301-7. PubMed ID: 25585539
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251.
Luan S; Sun L; Huang F
Arch Med Res; 2010 Feb; 41(2):67-74. PubMed ID: 20470934
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.
Yang F; Li QJ; Gong ZB; Zhou L; You N; Wang S; Li XL; Li JJ; An JZ; Wang DS; He Y; Dou KF
Technol Cancer Res Treat; 2014 Feb; 13(1):77-86. PubMed ID: 23862748
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer.
Wei C; Luo Q; Sun X; Li D; Song H; Li X; Song J; Hua K; Fang L
Int J Clin Exp Pathol; 2015; 8(7):7729-39. PubMed ID: 26339338
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-34a induces a senescence-like change via the down-regulation of SIRT1 and up-regulation of p53 protein in human esophageal squamous cancer cells with a wild-type p53 gene background.
Ye Z; Fang J; Dai S; Wang Y; Fu Z; Feng W; Wei Q; Huang P
Cancer Lett; 2016 Jan; 370(2):216-21. PubMed ID: 26523671
[TBL] [Abstract][Full Text] [Related]
8. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.
Nalls D; Tang SN; Rodova M; Srivastava RK; Shankar S
PLoS One; 2011; 6(8):e24099. PubMed ID: 21909380
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
10. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
[TBL] [Abstract][Full Text] [Related]
11. Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52.
Li G; Yao L; Zhang J; Li X; Dang S; Zeng K; Zhou Y; Gao F
Tumour Biol; 2016 Jun; 37(6):7481-91. PubMed ID: 26678891
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells.
Akao Y; Noguchi S; Iio A; Kojima K; Takagi T; Naoe T
Cancer Lett; 2011 Jan; 300(2):197-204. PubMed ID: 21067862
[TBL] [Abstract][Full Text] [Related]
13. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents.
Do MT; Kim HG; Choi JH; Jeong HG
Free Radic Biol Med; 2014 Sep; 74():21-34. PubMed ID: 24970682
[TBL] [Abstract][Full Text] [Related]
14. Expanding the Biotherapeutics Realm via miR-34a: "Potent Clever Little" Agent in Breast Cancer Therapy.
Mohammady M; Ghetmiri SI; Baharizade M; Morowvat MH; Torabi S
Curr Pharm Biotechnol; 2019; 20(8):665-673. PubMed ID: 31244419
[TBL] [Abstract][Full Text] [Related]
15. microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status.
Wang X; Dong K; Gao P; Long M; Lin F; Weng Y; Ouyang Y; Ren J; Zhang H
Cancer Biother Radiopharm; 2013 Feb; 28(1):45-50. PubMed ID: 23036084
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-34a Inhibition of the TLR Signaling Pathway Via CXCL10 Suppresses Breast Cancer Cell Invasion and Migration.
Xu M; Li D; Yang C; Ji JS
Cell Physiol Biochem; 2018; 46(3):1286-1304. PubMed ID: 29689563
[TBL] [Abstract][Full Text] [Related]
17. MiR-34a reverses radiation resistance on ECA-109 cells by inhibiting PI3K/AKT/mTOR signal pathway through downregulating the expression of SIRT1.
Ye Z; Xie T; Yan F; Wang L; Fang J; Wang Z; Hu F; Wang F; Fu Z
Int J Radiat Biol; 2021; 97(4):452-463. PubMed ID: 33507132
[TBL] [Abstract][Full Text] [Related]
18. EGCG enhances cancer cells sensitivity under
Kang Q; Zhang X; Cao N; Chen C; Yi J; Hao L; Ji Y; Liu X; Lu J
Food Chem Toxicol; 2019 Nov; 133():110807. PubMed ID: 31494133
[TBL] [Abstract][Full Text] [Related]
19. 0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loop.
Xia C; Shui L; Lou G; Ye B; Zhu W; Wang J; Wu S; Xu X; Mao L; Xu W; Chen Z; Liu Y; Zheng M
Sci Rep; 2017 Jun; 7(1):4396. PubMed ID: 28667294
[TBL] [Abstract][Full Text] [Related]
20. MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2.
Wang XF; Shi ZM; Wang XR; Cao L; Wang YY; Zhang JX; Yin Y; Luo H; Kang CS; Liu N; Jiang T; You YP
J Cancer Res Clin Oncol; 2012 Apr; 138(4):573-84. PubMed ID: 22207524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
